Mark D Pegram

List of Publications by Year
in descending order

79 papers	21,461 citations	145106 33 h-index	81351 76 g-index
80 all docs	80 docs citations	80 times ranked	19213 citing authors

#	Article	IF	Citations
1	Role of FcÎ³ receptors in HER2-targeted breast cancer therapy. , 2022, 10, e003171.		47
2	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clinical Cancer Research, 2022, 28, 1258-1267.	3.2	31
3	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. Cancer Research, 2022, 82, PD8-01-PD8-01.	0.4	4
4	Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nature Biotechnology, 2021, 39, 357-367.	9.4	163
5	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
6	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. JAMA Oncology, 2021, 7, 573.	3.4	217
7	First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibodyâ€“Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Molecular Cancer Therapeutics, 2021, 20, 1442-1453.	1.9	38
8	Single-cell immunoblotting resolves estrogen receptor-Î± isoforms in breast cancer. PLoS ONE, 2021, 16, e0254783.	1.1	5
9	Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	67
10	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology, 2021, 39, 2667-2675.	0.8	58
11	Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. Clinical Breast Cancer, 2021, 21, e340-e361.	1.1	10
12	Biosimilars in an era of rising oncology treatment options. Future Oncology, 2021, 17, 3881-3892.	1.1	5
13	Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Clinical Breast Cancer, 2021, 21, 383-390.	1.1	18
14	A careful reassessment of anthracycline use in curable breast cancer. Npj Breast Cancer, 2021, 7, 134.	2.3	25
15	Reply to J. Wei et al. Journal of Clinical Oncology, 2021, , JCO2101973.	0.8	1
16	A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clinical Breast Cancer, 2020, 20, e251-e260.	1.1	15
17	HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibodyâ€“Drug Conjugate Drug Development in Solid Tumors. Clinical Cancer Research, 2020, 26, 775-786.	3.2	36
18	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	13.9	789

#	Article	IF	Citations
19	A Novel HER2-targeted Antibodyâ€“drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels. Molecular Cancer Therapeutics, 2020, 19, 1866-1874.	1.9	11
20	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. Journal of Clinical Oncology, 2020, 38, 1070-1080.	0.8	19
21	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer, 2020, 20, 183-193.	1.1	13
22	Extracellular Vesicleâ€“Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity. Molecular Cancer Therapeutics, 2020, 19, 858-867.	1.9	33
23	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. Frontiers in Genetics, 2020, 11, 598118.	1.1	18
24	SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. Journal of Clinical Oncology, 2020, 38, 1040-1040.	0.8	2
25	Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.. Journal of Clinical Oncology, 2020, 38, 578-578.	0.8	5
26	Induced pluripotent stem cells as a novel cancer vaccine. Expert Opinion on Biological Therapy, 2019, 19, 1191-1197.	1.4	10
27	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2â€“positive breast cancer. European Journal of Cancer, 2019, 120, 1-9.	1.3	39
28	First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology, 2019, 37, 946-953.	0.8	377
29	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer, 2019, 120, 172-182.	2.9	43
30	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).. Journal of Clinical Oncology, 2019, 37, 1000-1000.	0.8	71
31	Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.. Journal of Clinical Oncology, 2019, 37, 580-580.	0.8	3
32	Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation. Molecular Cancer Therapeutics, 2018, 17, 1133-1142.	1.9	107
33	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment, 2018, 169, 1-7.	1.1	12
34	Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution. Npj Precision Oncology, 2018, 2, 10.	2.3	11
35	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 65-77.	1.8	11
36	Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research, 2018, 20, 52.	2.2	12

#	Article	IF	Citations
37	A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 3002-3002.	0.8	13
38	Quantitative measurement of total erbB2 (H2T), p110 t-erbB2, and erbB2:erbB3 (H23D) heterodimer expression and p110 t-erbB2 in malignant progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).. Journal of Clinical Oncology, 2018, 36, 12089-12089.	0.8	0
39	Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5687-5695.	3.2	170
40	A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).. Journal of Clinical Oncology, 2017, 35, TPS1107-TPS1107.	0.8	1
41	Hydrogel Poreâ€Size Modulation for Enhanced Singleâ€Cell Western Blotting. Advanced Materials, 2016, 28, 327-334.	11.1	57
42	Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Research, 2016, 76, 3702-3710.	0.4	51
43	Neratinib in ERBB2-Positive Brain Metastases. JAMA Oncology, 2016, 2, 1541.	3.4	8
44	Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumor Biology, 2016, 37, 9825-9835.	0.8	52
45	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. International Journal of Biochemistry and Cell Biology, 2016, 71, 12-23.	1.2	22
46	Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research, 2016, 18, 34.	2.2	34
47	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2016, 22, 3755-3763.	3.2	167
48	Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2^{mut} MBC).. Journal of Clinical Oncology, 2016, 34, 516-516.	0.8	13
49	SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, TPS630-TPS630.	0.8	4
50	A Phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI4276 in patients with select HER2-expressing advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS632-TPS632.	0.8	2
51	â€œVerticalâ€•Inhibition of HER2 Yields Horizontal Gains in the Clinic. Clinical Cancer Research, 2015, 21, 2663-2665.	3.2	2
52	Rapid Reduction in Breast Cancer Mortality With Inorganic Arsenic in Drinking Water. EBioMedicine, 2014, 1, 58-63.	2.7	28
53	Association Studies of FcÎ³ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunology Research, 2014, 2, 962-969.	1.6	44
54	Treating the HER2 Pathway in Early and Advanced Breast Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 751-765.	0.9	15

#	Article	IF	Citations
55	Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).. Cancer Research, 2013, 73, LB-63-LB-63.	0.4	23
56	Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. Breast Cancer Research and Treatment, 2012, 135, 79-91.	1.1	51
57	PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Research and Treatment, 2012, 136, 683-692.	1.1	36
58	Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 367, 1783-1791.	13.9	3,020
59	Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer. Breast Cancer, 2012, 19, 95-103.	1.3	5
60	Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptorâ€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 5538-5546.	0.8	948
61	Can We Circumvent Resistance To ErbB2-Targeted Agents By Targeting Novel Pathways?. Clinical Breast Cancer, 2008, 8, S121-S130.	1.1	22
62	Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of Clinical Oncology, 2008, 26, 3317-3323.	0.8	118
63	Augmented HER-2â€“Specific Immunity during Treatment with Trastuzumab and Chemotherapy. Clinical Cancer Research, 2007, 13, 5133-5143.	3.2	194
64	Application and potential limitations of animal models utilized in the development of trastuzumab (HerceptinÂ®): A case study. Advanced Drug Delivery Reviews, 2006, 58, 723-734.	6.6	62
65	Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells. Cancer Research, 2006, 66, 1630-1639.	0.4	846
66	Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 759-769.	3.0	271
67	Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 739-749.	3.0	488
68	Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINNTM Linker. Journal of Experimental Therapeutics and Oncology, 2003, 3, 27-35.	0.5	26
69	Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer. Journal of the National Cancer Institute, 2003, 95, 142-153.	3.0	522
70	Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/ protein and vascular endothelial growth factor. Seminars in Oncology, 2002, 29, 29-37.	0.8	73
71	Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 2001, 344, 783-792.	13.9	10,216
72	Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Research and Treatment, 2001, 67, 223-233.	1.1	31

#	Article	IF	Citations
73	HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Research and Treatment, 2001, 69, 53-63.	1.1	21
74	Docetaxel and Herceptin: Foundation for Future Strategies. Oncologist, 2001, 6, 22-25.	1.9	11
75	Docetaxel and Herceptin: Foundation for Future Strategies. Oncologist, 2001, 6, 22-25.	1.9	10
76	Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 1999, 18, 2241-2251.	2.6	645
77	Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene, 1999, 18, 6050-6062.	2.6	131
78	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 1998, 17, 2235-2249.	2.6	353
79	The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 1997, 15, 537-547.	2.6	317